CLVT · Clarivate Plc

The thesis

Clarivate's shares are more likely to lag the S&P 500 over the next three months. The debt reduction paid for by the life-sciences sale is now in the price, and organic recurring revenue growth of 1.3% in the third quarter of 2026 is too slow to move the shares further before management's 2027 guidance, which the company says comes in February.

The company is now two businesses: Academia & Government (A&G), which sells research databases such as Web of Science, and Intellectual Property (IP), which sells patent and trademark data. Clarivate closed the sale of its Life Sciences & Healthcare (LS&H) unit on 6 October 2026 for net cash proceeds of $488.4 million, according to its third-quarter release. That cash is going into debt, not shares. On 10 November 2026 the company priced tender offers for up to $415 million of its 2028 notes and $118 million of its 2029 notes, and expects settlement on 13 November 2026.

The shares closed at $2.32 on 11 November 2026, up 18.4% over three months. Goldman Sachs cut its target to $2.30 from $2.60 on 5 November 2026 and kept a Neutral rating. The price already reflects the deleveraging: it sits on Goldman's target one week after the tender was launched. The rating is LOW because the next fact that could re-rate the business, the 2027 outlook, is due in February, at or past the end of a three-month window.

Bullish and bearish views on Clarivate Plc

The bull case on Clarivate Plc (CLVT), in brief: Debt is being retired below par. The bear case: Growth is still near zero.

Bull case

• Debt is being retired below par. The 10 November 2026 pricing release set the 2028 notes at $979.08 and the 2029 notes at $928.75 per $1,000 of principal, so each dollar of cash retires more than a dollar of debt. Chief Financial Officer Michael Easton said on the 3 November 2026 call that the company expects to cut debt by about $875 million in 2026.
• Recurring growth is turning up. Organic annual contract value (ACV) rose 1.8% year on year at 30 September 2026, and the company guides fourth-quarter recurring organic growth of 2.00%–2.50%, above the full-year 1.00%–1.50% range (third-quarter release, 3 November 2026).
• IP contract value is growing again. Chief Executive Matti Shem Tov said on the 3 November 2026 call that IP ACV has returned to growth for the first time in over three years, citing a US Patent and Trademark Office trademark image-search win.
• Cash generation is large against the share price. The company guides 2026 free cash flow of $320–$340 million and said on the 3 November 2026 call that it expects 10%–15% free cash flow growth in 2027, helped by about $25 million lower cash interest.
• Its data now plugs into AI assistants. Clarivate put CompuMark trademark data into Microsoft Copilot on 2 November 2026 and Derwent and Darts-ip patent data into Anthropic's Claude on 11 November 2026, both through its IPOne platform. Management reported more than 465 million AI API calls on the 3 November 2026 call, over 2.5 times the prior year's volume.

Bear case

• Growth is still near zero. Continuing-operations revenue was $481.6 million in the third quarter of 2026, against $530.3 million a year earlier, and organic revenue grew 0.4% (third-quarter release, 3 November 2026). Transactional revenue fell 12.4% organically.
• Leverage remains heavy. Total debt was $4,176.1 million and cash $257.0 million at 30 September 2026, per the third-quarter release. The planned debt reduction leaves most of that in place.
• Losses continue under GAAP. The third-quarter net loss was $80.8 million, including a $62.2 million non-cash LS&H goodwill impairment. The company lowered its 2026 GAAP earnings-per-share (EPS) outlook to a loss of $0.65 to $0.62 on 3 November 2026.
• Fourth-quarter guidance sits below expectations. The company guided fourth-quarter adjusted EPS of $0.14–$0.18 on 3 November 2026, against a $0.19 consensus reported by Benzinga the same day.
• Sell-side targets sit at the price. Goldman Sachs's $2.30 target (5 November 2026) is below the 11 November 2026 close, leaving the shares no room to its fair-value estimate.
• Insiders have not bought. SEC Form 4 filings from August to October 2026 show only share grants and tax withholding, such as 263,576 shares withheld from LS&H President Henry Levy at $1.47 on 6 October 2026, and no open-market purchases.

Price setup

The shares closed at $2.32 on 11 November 2026, above the 50-day moving average of $1.84 and the 200-day moving average of $2.20, both as of that close. The 52-week closing low was $1.45 on 5 October 2026, the day before the LS&H sale closed. The 52-week intraday high was $3.87 on 28 November 2025, and the last close is 40.1% below it.

The November rally followed company news. The shares closed at $2.12 on 4 November 2026, the day the tender offers were launched, and at $2.33 on 5 November 2026. They held between $2.32 and $2.39 through 11 November 2026. The 200-day average is the level the recovery has to hold. A close back under it would put the shares back in the range they traded before the tender.

Catalysts ahead

• 13 November 2026: Settlement of the tender offers for the 2028 and 2029 notes. Fixes how much principal the LS&H proceeds retire, and at what discount, against the roughly $875 million 2026 debt-reduction target management gave on 3 November 2026.
• ~18 November 2026 (est.): CEO and CFO presentation at the RBC Capital Markets Global Technology, Internet, Media and Telecommunications Conference. First public update after the tender; any comment on fourth-quarter ACV or 2027 growth would test the 2.00%-2.50% fourth-quarter recurring growth guide.
• ~25 February 2027 (est.): Q4 2026 results and 2027 guidance. Shows whether recurring organic growth reached the 2.00%-2.50% fourth-quarter guide and whether 2027 guidance backs the 10%-15% free cash flow growth management described.

What would change the view

A weekly close above $2.39, the 10 November 2026 close and the top of the post-tender rally, which would show the shares leading; or a 2027 outlook projecting recurring organic revenue growth above 2.50%, the top of the fourth-quarter 2026 guide.

What it trades with

Clarivate is grouped with AI enterprise software names such as EPAM, Appian and Procore. Its shares have moved on its own balance-sheet events instead. The two largest November moves came on the tender launch and the third-quarter report, not on any peer's results. The shares are more likely to track credit conditions and the price of its own notes than software multiples. The AI link runs both ways: assistant integrations widen the reach of its data, and the same tools could replace part of what customers pay for. Third-quarter 2026 numbers do not yet show either effect in revenue.